Evidence map›Paper›PMID 26793049›Full record

ReviewFrontiers in neuroscience2015

Turning On Lights to Stop Neurodegeneration: The Potential of Near Infrared Light Therapy in Alzheimer's and Parkinson's Disease.

Daniel M Johnstone, Cécile Moro, Jonathan Stone, Alim-Louis Benabid, John Mitrofanis

5 registry-linked trialsOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in neuroscience, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 76 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 3 pooled it
14.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02817061 early_phase1completednot on this mapstarted 2018, after this paper: background citation

Effectiveness of Light for Enhancement of Cognition by Transcranial Repeated Application (ELECTRA): a Placebo-Controlled Study of Efficacy, Tolerability and Acceptability in Healthy Adult Volunteers

TypeinterventionalSponsorMassachusetts General HospitalRan2018 to 2019Enrolled80ConditionsDisease Type and/or Category Not ApplicableArmsOmnilux
NCT03724136 naunknown statusnot on this mapstarted 2018, after this paper: background citation

Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study

TypeinterventionalSponsorMD Stem CellsRan2018 to 2025Enrolled100ConditionsAlzheimer Disease, Alzheimer Dementia, Vascular Dementia, Lewy Body DiseaseArmsIntravenous Bone Marrow Stem Cell (BMSC) Fraction, Intranasal Topical Bone Marrow Stem Cell (BMSC) Fraction, Near Infrared Light
NCT04261569 naactive not recruitingnot on this mapstarted 2020, after this paper: background citation

Clinical Trial for Near Infrared Endoventricular Illumination for Neuroprotection in Very Early Cases of Parkinson's Disease (Ev-NIRT)

TypeinterventionalSponsorUniversity Hospital, GrenobleRan2020 to 2032Enrolled14ConditionsVery Early Stage of Parkinson's DiseaseArmsEv-NIRT
NCT04651426 nacompletednot on this mapstarted 2019, after this paper: background citation

Use of a Non-medicated Plaster in Chronic Lumbar Back Pain.

TypeinterventionalSponsorAzienda Ospedaliera Universitaria Integrata VeronaRan2019 to 2019Enrolled54ConditionsBack PainArmsThe FIT Therapy patch (D. FENSTEC s.r.l. Altavilla Vicentina, Italy) is a medical device class 1
NCT06352372 phase2completednot on this mapstarted 2024, after this paper: background citation

Safety and Efficacy of Transcranial Photobiomodulation (tPBM) for Individuals With Autism Spectrum Disorder and Epileptiform Activity

TypeinterventionalSponsorRichard FryeRan2024 to 2026Enrolled6ConditionsAutism Spectrum Disorder, EEG With Periodic Abnormalities, Epilepsy, Neurodevelopmental DisordersArmsnoninvasively delivered near infra-red (NIR) light - transcranial Photobiomodulation (tPBM)
3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 3 syntheses or guidelines pooled it, 166 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Review
  7. Transcranial photobiomodulation for the treatment of chemobrain: new perspectives from a pilot study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Daniel M JohnstoneDepartment of Physiology, University of Sydney Sydney, NSW, Australia.
Cécile MoroUniversity Grenoble Alpes, CEA, LETI, CLINATEC, MINATEC Campus Grenoble, France.
Jonathan StoneDepartment of Physiology, University of Sydney Sydney, NSW, Australia.
Alim-Louis BenabidUniversity Grenoble Alpes, CEA, LETI, CLINATEC, MINATEC Campus Grenoble, France.
John MitrofanisUniversity Grenoble Alpes, CEA, LETI, CLINATEC, MINATEC Campus Grenoble, France.
Clinatec · FRThe University of Sydney · AULaboratoire d'Électronique des Technologies de l'Information · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's and Parkinson's disease are the two most common neurodegenerative disorders. They develop after a progressive death of many neurons in the brain. Although therapies are available to treat the signs and symptoms of both diseases, the progression of neuronal death remains relentless, and it has proved difficult to slow or stop. Hence, there is a need to develop neuroprotective or disease-modifying treatments that stabilize this degeneration. Red to infrared light therapy (λ = 600-1070 nm), and in particular light in the near infrared (NIr) range, is emerging as a safe and effective therapy that is capable of arresting neuronal death. Previous studies have used NIr to treat tissue stressed by hypoxia, toxic insult, genetic mutation and mitochondrial dysfunction with much success. Here we propose NIr therapy as a neuroprotective or disease-modifying treatment for Alzheimer's and Parkinson's patients.

Indexed as

amyloid plaquesdisease-modifyingneuroprotectionphotobiomodulationtau protein

Identifiers

PMID26793049
PMCPMC4707222
OpenAlexW2264781189

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.